BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36370087)

  • 21. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia.
    Kumar S; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2001 Nov; 28(10):951-6. PubMed ID: 11753550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preconditioning Absolute Lymphocyte Count and Transplantation Outcomes in Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Reduced-Intensity Conditioning and Antithymocyte Globulin Treatment.
    Woo GU; Hong J; Kim H; Byun JM; Koh Y; Shin DY; Kim I; Yoon SS
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):1855-1860. PubMed ID: 32561338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does Lymphocyte Count Impact Dosing of Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplantation?
    Heelan F; Mallick R; Bryant A; Radhwi O; Atkins H; Huebsch L; Bredeson C; Allan D; Kekre N
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1298-1302. PubMed ID: 32165325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
    Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P
    Front Immunol; 2023; 14():1191382. PubMed ID: 37469510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How close are we to CAR T-cell therapy for AML?
    Gill SI
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101104. PubMed ID: 31779970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
    Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
    Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation.
    Atta EH; de Azevedo AM; Maiolino A; Coelho CJ; Sarcinelli SM; de Alvarenga Máximo C; Marra VL
    Am J Hematol; 2009 Jan; 84(1):21-8. PubMed ID: 19006229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
    Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
    Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis.
    Zhang H; Bu C; Peng Z; Li G; Zhou Z; Ding W; Zheng Y; He Y; Hu Z; Pei K; Luo M; Li C
    Leukemia; 2022 Nov; 36(11):2596-2604. PubMed ID: 36151140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of pre-conditioning immunoglobulin and absolute lymphocyte count on the outcomes of allogeneic hematopoietic cell transplantation.
    Kaçmaz M; Başci S; Ilhan G; Yiğenoğlu TN; Çakar MK; Dal MS; Altuntaş F
    Transpl Immunol; 2023 Feb; 76():101776. PubMed ID: 36572120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptor T cell therapies for acute myeloid leukemia.
    Gu B; Chu J; Wu D
    Front Med; 2020 Dec; 14(6):701-710. PubMed ID: 33263835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma.
    Kim Y; Kim SJ; Cheong JW; Cho H; Chung H; Lee JY; Jang JE; Min YH; Kim JS
    Hematol Oncol; 2017 Dec; 35(4):465-471. PubMed ID: 27440113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies.
    Chang YJ; Zhao XY; Huo MR; Xu LP; Liu DH; Liu KY; Huang XJ
    Am J Hematol; 2011 Feb; 86(2):227-30. PubMed ID: 21264916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia.
    Zhang H; Wang P; Li Z; He Y; Gan W; Jiang H
    Clin Cancer Res; 2021 Jul; 27(13):3549-3555. PubMed ID: 33832948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early lymphocyte reconstitution is associated with improved transplant outcome after cord blood transplantation.
    Tedeschi SK; Jagasia M; Engelhardt BG; Domm J; Kassim AA; Chinratanalab W; Greenhut SL; Goodman S; Greer JP; Schuening F; Frangoul H; Savani BN
    Cytotherapy; 2011 Jan; 13(1):78-82. PubMed ID: 20586668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL.
    Korell F; Laier S; Sauer S; Veelken K; Hennemann H; Schubert ML; Sauer T; Pavel P; Mueller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Cells; 2020 May; 9(5):. PubMed ID: 32429189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia.
    Oberley MJ; Gaynon PS; Bhojwani D; Pulsipher MA; Gardner RA; Hiemenz MC; Ji J; Han J; O'Gorman MRG; Wayne AS; Raca G
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27265. PubMed ID: 29797659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia.
    Ishaqi MK; Afzal S; Dupuis A; Doyle J; Gassas A
    Bone Marrow Transplant; 2008 Feb; 41(3):245-52. PubMed ID: 17952129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.